Trial Profile
A Non-Interventional, Multicentre, Prospective, Observational Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Patients. (ONTARGET-India)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2017
Price :
$35
*
At a glance
- Drugs Saxagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ONTARGET-INDIA
- Sponsors AstraZeneca
- 22 Feb 2017 Status changed from active, no longer recruiting to completed.
- 29 Nov 2016 Planned number of patients changed from 1500 to 1200.
- 29 Nov 2016 Status changed from recruiting to active, no longer recruiting.